FDA Peptide Category Update: Clarifying Misinformation Cole Thomas posted on the topic LinkedIn The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 ( compounding only, no legal prescribing) into Category 1. This means The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Orthopedic Use of BPC 157 Sports Med Review